ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

被引：0

作者：

Park, W. ^{[1
]}

Kwon, D. ^{[2
]}

Desai, A. ^{[1
]}

Florou, V. ^{[1
]}

Saravia, D. ^{[3
]}

Warsch, J. ^{[4
]}

Chae, Y. K. ^{[5
]}

Ishkanian, A. ^{[6
]}

Jahanzeb, M. ^{[7
]}

Mudad, R. ^{[8
]}

Lopes, G. ^{[9
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA

[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA

[3] Univ Miami, Miller Sch Med, Internal Med, Miami, FL 33136 USA

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA

[5] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA

[7] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Univ Miami, Sylvester Comprehens Canc Ctr, Global Oncol, Miami, FL USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

Predictive; PD-1; inhibitor; Clinical outcome;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.07-024

引用

页码：S2004 / S2004

页数：1

共 50 条

[11] iSEND is an algorithmic model specific for advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors
Park, Wungki
Florou, Vaia
Algaze, Sandra
Saravia, Diana
Kwon, Deukwoo
Lopes, Gilberto
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[12] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
Ma, K.
Guo, Y.
Wang, Y.
Wang, X.
Xu, Y.
Sun, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
[13] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Janning, Melanie
Kobus, Franca
Babayan, Anna
Wikman, Harriet
Velthaus, Janna-Lisa
Bergmann, Sonja
Schatz, Stefanie
Falk, Markus
Berger, Lars-Arne
Boettcher, Lisa-Marie
Paesler, Sarina
Gorges, Tobias M.
O'Flaherty, Linda
Hille, Claudia
Joosse, Simon A.
Simon, Ronald
Tiemann, Markus
Bokemeyer, Carsten
Reck, Martin
Riethdorf, Sabine
Pantel, Klaus
Loges, Sonja
CANCERS, 2019, 11 (06):
[14] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
Wen, Wen
Zhang, Yong
Zhang, Hua
Chen, Yingshuang
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 969 - 978
[15] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
Wen Wen
Yong Zhang
Hua Zhang
Yingshuang Chen
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 969 - 978
[16] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
Monneur, Audrey
Goncalves, Anthony
Bertucci, Francois
BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
[17] PD-1/PD-L1 Inhibitors in Cervical Cancer
Liu, Yuncong
Wu, Li
Tong, Ruizhan
Yang, Feiyue
Yin, Limei
Li, Mengqian
You, Liting
Xue, Jianxin
Lu, You
FRONTIERS IN PHARMACOLOGY, 2019, 10
[18] Dynamic changes of patelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC
Zhou, F.
Xiong, A.
Zhou, C.
ANNALS OF ONCOLOGY, 2019, 30
[19] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Qian
Han, Jingjing
Yang, Yonglin
Chen, Yu
FRONTIERS IN IMMUNOLOGY, 2022, 13
[20] PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Zhang, Ke
Kong, Xiangyi
Li, Yuan
Wang, Zhongzhao
Zhang, Lin
Xuan, Lixue
FRONTIERS IN PHARMACOLOGY, 2022, 13

← 1 2 3 4 5 →